CGC vs. AMRX, DCPH, BHC, CPRX, AMPH, GMTX, SNDX, IMCR, EWTX, and ARVN
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), Gemini Therapeutics (GMTX), Syndax Pharmaceuticals (SNDX), Immunocore (IMCR), Edgewise Therapeutics (EWTX), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Canopy Growth (NASDAQ:CGC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
Amneal Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Amneal Pharmaceuticals has higher revenue and earnings than Canopy Growth. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Amneal Pharmaceuticals presently has a consensus target price of $8.25, indicating a potential upside of 11.04%. Canopy Growth has a consensus target price of $4.53, indicating a potential downside of 37.38%. Given Canopy Growth's stronger consensus rating and higher possible upside, research analysts plainly believe Amneal Pharmaceuticals is more favorable than Canopy Growth.
In the previous week, Canopy Growth had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Canopy Growth and 3 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.07 beat Canopy Growth's score of 0.80 indicating that Canopy Growth is being referred to more favorably in the news media.
Canopy Growth received 11 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 19.42% of users gave Canopy Growth an outperform vote.
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Amneal Pharmaceuticals has a net margin of -6.76% compared to Amneal Pharmaceuticals' net margin of -185.77%. Canopy Growth's return on equity of 234.06% beat Amneal Pharmaceuticals' return on equity.
Summary
Amneal Pharmaceuticals beats Canopy Growth on 13 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
